1. health and fitness
2. disease
3. cancer

Clinical Studies Summary
Prostate HistoScanning™
A tissue characterisation technology
supporting prostate cancer care
Introduction
•• HistoScanning™ is a new non-invasive tissue characterisation technology based on ultrasonography. It consists of a computeraided analysis of native ultrasound radiofrequency volume data to identify patterns in glandular tissue in order to detect
differentiated tissue.
•• Prostate HistoScanning™ is the commercially available transrectal ultrasound-based product of HistoScanning™, specifically
conceived to detect suspicious areas in the prostate. Because of its unique ability to accurately identify, locate and assess
the size of differentiated prostate tissue, Prostate HistoScanning™ may guide clinical decisions throughout entire prostate
cancer care: detection and diagnosis, treatment planning, treatment guidance and post-treatment monitoring (Figure 1).
•• To date over 1,500 patients have been enrolled in clinical studies on Prostate HistoScanning™ and more than 16,000 patients
have benefited already from it in clinical practice.
Tissue Characterisation with Prostate HistoScanning™
Detection and
Diagnosis
Treatment
planning
Treatment
guidance
Surveillance
FIGURE 1.
Tissue Characterisation with Prostate HistoScanning™
Detection and
Diagnosis
Treatment
Treatment
Surveillance
Visual Reassurance
for Decision Making
and True Targeting
planning
guidance
Detection and diagnosis
•• Prostate HistoScanning™ is often used in clinical practice
to determine the need for prostate biopsy and aid in
biopsy planning.
•• The ability of Prostate HistoScanning™ to predict biopsy
outcome has been evaluated in several clinical studies.1-6
% men with ≥ 1 positive
biopsy core
100
Determining biopsy need and
predicting biopsy outcome
•• In 2 single-centre pilot studies, 42-50 men with an
First biopsy
Repeat biopsy
80
75%
60
If THV < 0.20 mL,
40 0% of men had
50%
Prostate HistoScanning™ and thereafter had a first or
repeat biopsy.1,2
60%
a positive biopsy
20
0
< 0.20
0.20-0.49
0.50-0.99
≥ 1.00
THV (mL)
elevated prostate-specific antigen (PSA) level and/or
suspicious digital rectal examination (DRE) underwent
54%
81% 83%
FIGURE 3. The higher the median total cancer volume as
determined by Prostate HistoScanning™ (THV) the higher the
probability of a positive biopsy.1,2
•• Men with a positive first or repeat biopsy had a
statistically significantly larger median total cancer
biopsy (maximum 9 cores) in suspicious areas based on
volume as determined by Prostate HistoScanning™ (Total
Prostate HistoScanning™.7
HistoScanning Volume [THV]) compared to men with a
•• Prostate cancer was detected in 28 of 80 men (35%).
negative biopsy (Figure 2).
•• A total of 79% of all cancers were detected via the
14-core transrectal biopsy (Figure 4). Despite using a
maximum of only 9 cores, the transperineal Prostate
HistoScanning™-targeted biopsy detected 82% of all
cancers.
1.79
1.5
1
P<0.0001
0.71
0.5
0
0.10
0.30
Negative
(N=19)
≥ 1 positive core
(N=23)
Negative
(N=32)
Initial biopsy
≥ 1 positive core
(N=18)
Repeat biopsy
FIGURE 2. The median total cancer volume as determined by
Prostate HistoScanning™ (THV) is statistically significantly higher
in case of a positive biopsy vs. a negative biopsy.1,2
•• A higher median THV corresponded with a higher
percentage of men having a positive biopsy (Figure 3).1,2
% of all detected
prostate cancers (N=28)
Median THV (mL)
2
P=0.0007
100
80
60
79%
82%
14 cores
Max
9 cores
40
20
0
Systematic
transrectal biopsy
Transperineal
HistoScanning™targeted biopsy
FIGURE 4. Transperineal Prostate HistoScanning™ cognitivetargeted biopsy achieves similar prostate cancer detection rates
as systematic transrectal biopsy while reducing the number of
cores needed.7
In case of a median THV < 0.20 mL, no positive biopsies
were observed.
•• The cognitive targeted biopsy using Prostate
HistoScanning™ by the transperineal approach thus
Targeting biopsies
resulted in similar prostate cancer detection rates as the
•• Prostate HistoScanning™ may not only predict biopsy
outcome but also aid in targeting biopsies by indicating
suspicious areas in the prostate.
7,8
14-core systematic transrectal biopsy while reducing the
number of cores.
•• By reducing the number of cores needed, Prostate
•• A study was performed in 80 men who underwent
HistoScanning™ may aid in decreasing local tissue
a systematic 14-core transrectal biopsy which was
trauma and complications, patients’ pain and discomfort
supplemented with a cognitive targeted transperineal
and the surgical effort.
Clinical results of Prostate HistoScanning™
Treatment planning
•• Knowledge of the location and size of tumours may be
To provide direct instead of cognitive guidance in
transrectal ultrasound-based biopsy, the Prostate
HistoScanning™ TT system has been developed with
the ability to aid in biopsy needle orientation and
continuously monitor and document the planned
prostate biopsy. Prostate HistoScanning™ TT
complements Tissue Characterisation with True
Targeting functionality.
useful for treatment planning of a nerve-sparing radical
prostatectomy.
•• A retrospective study in 80 patients who had undergone
Prostate HistoScanning™ and radical prostatectomy
assessed whether Prostate HistoScanning™ could predict
a negative surgical margin.12
•• It was shown that when no Prostate HistoScanning™
For the definition and functionality of Prostate
volume or a volume < 0.20 mL was found at the left or
HistoScanning™ TT and True Targeting, refer to product
right side of the prostate, the probability of a negative
documentation MK2U00146D-EN.
surgical margin at that side was 91%.
•• On multivariate analysis, the presence of a Prostate
HistoScanning™ focus volume ≥ 0.20 mL was associated
Detecting significant cancer
with a 3.7-fold increased risk of a positive surgical margin
•• Prostate HistoScanning™ has also been evaluated for its
(P=0.027; Figure 5).
use to discriminate between clinically insignificant and
significant prostate cancer.9-12
•• A study in 32 men demonstrated that Prostate
HistoScanning™ outcomes were statistically significantly
different between pT2 and pT3 and between
Gleason sum ≤ 6, 7 and ≥ 7 cancers.
9
•• Another single-centre study in a smaller population
comparing Prostate HistoScanning™ results with radical
prostatectomy specimens showed that the likelihood
(calculated as relative risk) of Prostate HistoScanning™
to accurately grade tumours as Gleason grade 4/5 vs.
3 was 3.2 (P<0.0001).10
•• Furthermore, a study in 85 men undergoing radical
prostatectomy demonstrated that the sensitivity of Prostate
HistoScanning™ focus
≥ 0.20 mL vs. < 0.20 mL
3.66 P=0.027
HistoScanning™ focus
≥ 0.50 mL vs. < 0.20 mL
3.84 P=0.012
Biopsy Gleason sum 4
vs. negative biopsy
3.88 P=0.005
0
1
2
3
4
5
6
Odds ratio for presence of positive surgical margin
at radical prostatectomy
FIGURE 5. The risk of a positive surgical margin increases
almost 4-fold in case of a Prostate HistoScanning™-detected
focus ≥ 0.20 mL.12
HistoScanning™ in detecting prostate cancer increases
with tumour stage, grade and volume (Table 1).11
•• In another study in 25 men (50 prostate lobes) scheduled
for nerve-sparing radical prostatectomy, the use of
TABLE 1. Sensitivity of Prostate HistoScanning™ increases
with higher pathological stage, grade and volume of prostate
cancer.11
Prostate HistoScanning™ in addition to standard preoperative clinical assessment and 3 T diffusion-weighted
(DW) magnetic resonance imaging (MRI) changed the
nerve-sparing approach in 32% of lobes.13 A trend for
pT2 (N=44)
pT3 (N=38)
All (N=85)
reduced use of intra-fascial and extra-fascial nerve-
61%
92%
74%
sparing, and increased use of side excision was apparent
Gleason sum 6
(N=9)
Gleason sum 7
(N=50)
Gleason sum ≥ 8
(N=18)
55%
74%
83%
Tumour volume
< 1 mL (N=10)
Tumour volume
1-5 mL (N=40)
Tumour volume
> 5 mL (N=35)
50%
58%
86%
after refined staging with Prostate HistoScanning™. This
was reflected in reduced positive margin rates.
•• These studies suggest that Prostate HistoScanning™ may
refine and optimise pre-operative staging resulting in an
oncologically safer nerve-sparing radical prostatectomy
and reduced positive margin rates.
Treatment guidance
Post-treatment monitoring
•• Because of its ability to characterise prostate tissue,
•• The ability of Prostate HistoScanning™ to accurately
Prostate HistoScanning™ may aid in guiding local
localise cancer foci enables its use for monitoring
prostate cancer therapy, such as brachytherapy.
patients for recurrent disease after prior prostate cancer
•• A prospective, single-centre, phase II study has explored
therapy.15,16
the feasibility of selectively escalating the dose in tumour
•• A study in 90 patients who had been previously treated
areas inside the prostate by image-guided interstitial pulse-
with high-intensity focused ultrasound (HIFU) for localised
dosed rate (PDR)/high-dose rate (HDR) brachytherapy,
prostate cancer used Prostate HistoScanning™ to identify
i.e. fine-tuned dose-painting that allows the creation of
suspicious areas after 1-7 years. All patients underwent
microboost volumes.
biopsy for histological verification.15
14
Prostate HistoScanning™ was
performed to detect high-risk areas.
•• Prostate HistoScanning™ demonstrated a high diagnostic
•• Table 2 presents the interim results of 19 patients.
performance in detecting recurrent cancer foci of
> 0.20 mL after prior HIFU therapy (Table 3).
TABLE 2. Feasibility of Prostate HistoScanning™ in determining
brachytherapy areas.14
Dosimetric
quantifier (N=19)
Prostate
Median V100
99%
Median D90
112%
Prostate HistoScanning™
defined high-risk areas
TABLE 3. Diagnostic performance* of Prostate HistoScanning™
in detecting recurrent cancer foci > 0.20 mL after prior HIFU
therapy.15
Volume of suspicious area
124%
Median V120
94%
Median V130
85%
Dx: dose that covers x% of the prostate volume; Vx: fractional
volume of the prostate that received x% of the prescription dose.
< 0.20 mL
(N=51)
0.20-0.50 mL
(N=24)
> 0.50 mL
(N=15)
Sensitivity
100%
96%
100%
Specificity
8%
88%
100%
* Reference test biopsy
•• A good tolerability without significant acute side effects
(no grade ≥ 3 toxicities) was shown during 3-months
follow-up.
•• This suggests that Prostate HistoScanning™ cognitive
guidance for brachytherapy allows significant dose
escalations as microboost to prostate tumour regions
while meeting stringent dose constraints for the adjacent
organs at risk.
Conclusions
Prostate HistoScanning™ can provide support to clinicians to make informed decisions
throughout prostate cancer treatment to provide optimal patient care:
• determining the need for biopsy
• prediction of biopsy outcome and improved targeting of biopsies
• guidance in treatment planning and execution
• aid in monitoring of patients after treatment
The technology
Clinical validation
•• Prostate HistoScanning™ is a tissue characterisation
•• Several studies have validated the ability of Prostate
technology using native radiofrequency data from
HistoScanning™ to identify and characterise cancer
transrectal ultrasound (TRUS) volume scans of
foci with histology results from radical prostatectomy
the prostate. The native radiofrequency data are
specimens as reference test.9,19-29
analysed by a set of validated, multiparametric
•• The exploratory, open-label, proof-of-concept study
mathematical algorithms to detect specific changes
PHS -01 demonstrated that the concordance in
in tissue characteristics. This results in a 3-dimensional
diameter of index tumour was high between Prostate
prostate image in which suspicious areas in the
HistoScanning™ and histology results (r=0.95,
prostate are labelled in colour, superimposed on
P<0.001).19 Moreover, there was a 100% concordance
top of the simultaneously processed grey-scale TRUS
in attribution of multifocality and laterality. Prostate
image (Figure 6). A special volumetric tool enables
HistoScanning™ performed well in detecting cancer
measurement of total prostate volume and volume of
foci ≥ 0.50 mL on histology (Table 4).20 There was a
suspicious areas.
strong correlation in lesion volumes (r=0.99, P<0.001)
•• Prostate HistoScanning™ can be easily integrated in the
and total cancer volume (r=0.98, P<0.001) between
existing clinical pathway and has a short acquisition
Prostate HistoScanning™ and radical prostatectomy
and analysis procedure. Inter-observer agreement for
histology.
presence or absence of cancer foci ≥ 0.50 mL in prostate
sextants has been reported to be high (75%‑90%).17,18
TABLE 4. Diagnostic performance* of Prostate HistoScanning™
in predicting lesions ≥ 0.50 mL in 13 patients with 28 lesions
(12 lesions ≥ 0.50 mL).20
Volume
threshold
a.
Foci ≥ 0.50 mL
Sensitivity Specificity
100%
(12/12)
81%
(13/16)
PPV
NPV
80%
(12/15)
100%
(13/13)
PPV: positive predictive value; NPV: negative predictive value
* Reference test radical prostatectomy
•• The multi-centre, European, prospective cohort study
PHS-02 in patients with organ-confined prostate cancer
b.
c.
scheduled for radical prostatectomy examined the
diagnostic accuracy of Prostate HistoScanning™ to
locate a cancer focus of at least 0.20 mL or 0.50 mL
in a sextant.21 Prostate HistoScanning™ showed 90%
sensitivity and 70%‑72% specificity for the correct
localisation and identification of lesions ≥ 0.20 mL
and ≥ 0.50 mL within a sextant compared with radical
prostatectomy histology (Table 5).
FIGURE 6. a. Example slice of a surgical specimen case CLI-001
b. View of grid analysis of the example slice case CLI-001
c. View in Prostate HistoScanning™ of the example slice case
CLI-001
Image courtesy of Prof. Dr. František Zát’ura, Univerzita Palackého v Olomouci
(UPOL) - Urologická klinika - Fakultní nemocnice, Czech Republic.
TABLE 5. Diagnostic performance* of Prostate HistoScanning™
to correctly identify prostate cancer in 23 patients (138 sextants)
with an index foci ≥ 0.50 mL and 27 patients (162 sextants) with
an index foci ≥ 0.20 mL.21
Volume
threshold
Sensitivity Specificity
PPV
NPV
Foci ≥ 0.50 mL
90%
(79/88)
70%
(35/50)
84%
(79/94)
80%
(35/44)
Foci ≥ 0.20 mL
90%
(87/97)
72%
(47/65)
83%
(87/105)
82%
(47/57)
PPV: positive predictive value; NPV: negative predictive value
* Reference test radical prostatectomy
References
1. Nørgaard N, Autier P. Can HistoScanning™ help in the assessment
of patients with raised serum PSA level: a pilot study. Eur Urol Suppl
2010;9:78 (abs. 147)
2. Zát`ura F, Klézl P, Bárta J, Autier P. Prostate HistoScanning™
examination in patients with past negative biopsy sessions: a pilot study.
BJU Int 2010;106 (Suppl 1):18 (abs. P7)
3. De Coninck V, Braeckman J. The value of Prostate HistoScanning™ in
men at risk of prostate cancer. Master thesis, May 2011
4. Epplen R, van Essen J, Pfister D, Porres D, Heidenreich A. Is
HistoScanning a valid tool to detect prostate cancer in repeat biopsy?
J Clin Oncol 2012 (Suppl 5):30 (abs. 57)
5. Fedorova A, Burdelova N, Emelyanova E, Churkina S, Ponomarenko I,
Alferov S, Zubarev A. First experience of combining use of
HistoScanning and sonoelastography in prostate cancer. Presented at
the European Congress of Radiotherapy (ECR) 2012, (abs. C-2609);
doi: 10.1594/ecr2012/C-2609
6. Köves B, Bõde I, Tenke P. The diagnostic value of Prostate
HistoScanning™ in the diagnosis of prostate cancer. Poster presented
at the Central European Meeting (CEM) of the European Association
of Urology (EAU) 2012
7. Hamann M, Hamann C, Schenk E, Al-Najar A, Naumann C,
Jünemann K. Computer-aided (HistoScanning) biopsies versus
conventional transrectal ultrasound-guided prostate biopsies: do
targeted biopsy schemes improve the cancer detection rate? Urology
2013;81:370-5
8. De Coninck V, Braeckman J, Autier P, Michielsen D. Computer-aided
ultrasonography-guided biopsy: accurate tool in prostate cancer
detection. Abstract presented at Global Congress on Prostate Cancer
2012, 28-30 June, Brussels, Belgium (abs. 36)
9. Chauhan S, Syed J, Sivaraman A, Schatloff O, Ortega F, Coelho
R,Palmer K. External validation of HistoScanning system to identify,
locate and characterise foci of prostate cancer. J Urol 2012;187
(4 Suppl):e496-7 (abs. 1227)
10. Simmons L, Autier P, Moore CM, Emberton M. Ultrasound spectral
interrogation of histological grade in prostate cancer using Prostate
HistoScanning™. Eur Urol Suppl 2011;10:302 (abs. 967)
11. Epplen R, van Essen J, van Erps T, Porres D, Pfister D, Heidenreich A.
Detection of prostate cancer with HistoScanning™, a novel ultrasound
based technique to detect and visualize changed in solid organ tissues:
a comparison with pathology findings in 85 patients. J Clin Oncol 2012
(Suppl 5):30 (abs. 53)
12. Salomon G, Spethmann J, Beckmann A, Autier P, Moore C, Durner L,
Sandmann M, Haese A, Schlomm T, Michl U, Heinzer H, Graefen M,
Steuber T. Accuracy of HistoScanning™ for the prediction of a negative
surgical margin in patients undergoing radical prostatectomy. BJU Int
2013;111:60-6
13. Leminski A, Simmons L, Rashid T, Monzon L, Hazell S,Winkler M. Preoperative staging of prostate cancer with HistoScanning™ facilitates
nerve-sparing prostatectomy and may increase complete excision of
prostate cancers. Urology 2011;78(Suppl 3A):S45-6 (abs. MP-03.15)
14. Lettmaier S, Kreppner S, Lotter M, Fietkau R, Strnad V. HistoScanning
based dose escalation for prostate cancer as microboost using
brachytherapy-a phase II trial. Radiother Oncol 2012;103 (Suppl 2):S72
(abs. PO-177)
15. Glybochko P, Alyaev Y, Amosov A, Krupinov G, Ganzha T, Obuhov A.
HistoScanning in monitoring of patients after prostate HIFU-ablation.
Presented at the 4th European Multidisciplinary Meeting on Urological
Cancers (EMUC) 2012 (abs. P084)
16. Shimko M, Knoedler J, Umbreit E, Mynderse L. Correlation of
3-dimensional ultrasound computer-aided interpretation with
dynamic contrast enhanced pelvic MRI in the detection of post
radical prostatectomy local recurrence of prostate cancer. J Urol
2010;183(4 Suppl):e783 (abs. 2018)
17. Van den Heuvel S, Simmons L, Autier P, Verhagen P, Moore C,
Emberton M, Bangma C. Inter-observer variability in the interpretation
of HistoScanning™ characterization of prostate cancer. Urology
2011;78(Suppl 3A):S24-5 (abs. POD-07.06)
18. Simmons L, Robertson N, Ahmed H, Moore C, Emberton M. Interoperator reliability of prostate HistoScanning™ for the characterization
of prostate cancer. Urology 2012;80 (Suppl 3A):S138-9 (abs. MP-14.15)
19. Braeckman J, Autier P, Garbar C, Pipeleers Marichal M, Soviany C,
Nir R, Nir D, Michielsen D, Bleiberg H, Egevad L, Emberton M.
Computer-aided ultrasonography (HistoScanning): a novel technology
for locating and characterizing prostate cancer. BJU Int 2008;101:293-8
20. Braeckman J, Autier P, Soviany C, Nir R, Nir D, Michielsen D,
Treurnicht K, Jarmulowicz M, Bleiberg H, Govindaraju S, Emberton
M. The accuracy of transrectal ultrasonography supplemented with
computer-aided ultrasonography for detecting small prostate cancers.
BJU Int 2008;102:1560-5
21. Simmons L, Autier P, Zát’ura F, Braeckman J, Peltier A, Romic I,
Stenzl A, Treurnicht K, Walker T, Nir D, Moor C, Emberton M.
Detection, localisation and characterisation of prostate cancer by
Prostate HistoScanning™. BJU Int 2012;110:28-35
22. Labanaris A, Eck A, Addali M, Afram S, Witt J, Zugor V. The value
of computer-aided ultrasonography in the detection and evaluation of
prostate cancer. Urology 2011;78 (Suppl 3A):S44-5 (abs. MP-03.12)
23. Simmons L, Leminski A, Rashid T, Monzon L, Hazell S, Winkler M.
Blinded comparison of HistoScanning™ volumetric tumour assessment
with whole mount step sectioned radical prostatectomy specimens.
Urology 2011;78 (Suppl 3A):S46 (abs. MP-03.16)
24. Markovsky O, Durner L, Sarbia M, Obernerder R, Kriegmair M.
Negative predictive value of prostate HistoScanning (computer-aided
tissue characterization for detection of prostate cancer): preliminary
results. Urology 2011;78 (Suppl 3A): S303 (abs. UP-02.126)
25. Epplen R, Eck A, Kowalke T, Zugor V, Afram S, Engels R, Zumbe J,
Pfister D, Porres D, Braunschweig T, Knueche R, Witt J, Heidenreich A.
Detection of prostate cancer by HistoScanning™- the Aachen, Gronau
and Leverkusen experience. A retrospective comparison in 282 patients
scheduled for radical prostatectomy. Urologe 2012;51 (Suppl 1):12
(abs. V1-1)
26. Macek P, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Ahallal Y,
Gaya J, Durand M, Cerruti J, Mascle M, Cathelineau X. Prostate
HistoScanning-Is it good for daily practice? Eur Urol Suppl 2012;11:S128
(abs. C.190)
27. Ganpule A, Mishra S, Ganesmoni R, Sabnis R, Desai M. Validation
of Prostate HistoScanning™ in localization of prostate carcinoma: The
Indian experience. Urology 2012;80(Suppl 3A):S138 (abs.MP-14.14)
28. Apolihin O, Sivkov A, Efremov G, Zhernov A, Zhukov O, Keshishev
N, Koryakin A. HistoScanning in PCa identification in patients with
previous negative biopsies. Presented at the 19th European Symposium
on Urogenital Radiology & 7th Britisch Society of Urogenital Radiology
(BSUR) Annual Scientific Meeting 2012 (abs. SSII.04)
29. Labanaris A, Eck A, Addali M, Witt J, Zugor V. HistoScanning: a new
diagnostic modality for the detection, localtion and tumour volume
determination of prostate cancer. Eur Urol Suppl 2012;11:S141
(abs. S.38)
For more information contact your local AMD representative.
Advanced Medical Diagnostics SA/NV/AG (AMD) • Waterloo Office Park • Drève Richelle 161 Bat i Bte 3 • B-1410 Waterloo • Belgium
T +32 23 528 048 • F +32 23 528 049 • E local.representation@histoscanning.com • www.histoscanning.com
Editorial support by Ismar Healthcare NV Belgium.
MK2U0399M-EN (03/2013 - © AMD) — 15 March 2013